Argenx US Patent-Cliff Exposure & CMS Drug Spending Portfolio
Argenx US (US): 1 reconciled FDA prescription therapies, $142.1M 2024 CMS Part D & Medicaid spend, and $66,928 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $142.1M |
| 2024 Medicare Part D Spend | $126.1M |
| 2024 Medicaid Spend | $16.0M |
| California HCAI SB 17 Filings | Specialty launch notice ($66,928 intro WAC) |